Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))

New sublingual delivery system designed to provide more rapid relief from nausea caused by cancer medicinesOndansetron, currently sold under the brand name Zofran®, was the 53rd most commonly prescribed medication in the U.S. in 2023Global …